RXDX-102 has been designated as a back-up compound to RXDX-101 and with respect to which the company will not devote further development resources unless the development program for RXDX-101 is unsuccessful (Filing 10-Q , Ignyta, MAY 12, 2014, View Source [SID:1234500513]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!